The C-terminal products of cellular prion protein processing, C1 and C2, exert distinct influence on p53-dependent staurosporine-induced caspase-3 activation

被引:66
作者
Sunyach, Claire [1 ]
Cisse, Moustapha Alfa [1 ]
da Costa, Cristine Alves [1 ]
Checler, Frederic [1 ]
机构
[1] Univ Nice Sophia Antipolis, Inst Pharmacol Mol & Cellulaire, CNRS, UMR6097,Equipe Labellisee,Fdn Rech Med, F-06560 Valbonne, France
关键词
D O I
10.1074/jbc.M609663200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The cellular prion protein ( PrPc) undergoes various endoproteolytic attacks within its N-terminal domain, leading to the production of C-terminal fragments ( C) tethered to the plasma membrane and soluble N-terminal peptides ( N). One of these cleavages occurs at position 110/111, thereby generating C1 and N1 products. We have reported that disintegrins ADAM-10, -9, and -17 participate either directly or indirectly to this proteolytic event. An alternative proteolytic event taking place around residue 90 yields C2 and N2 fragments. The putative function of these proteolytic fragments remained to be established. We have set up two novel human embryonic kidney 293 cell lines stably overexpressing either C1 or C2. Weshow that C1 potentiates staurosporine-induced caspase-3 activation through a p53-dependent mechanism. Thus, C1 positively controls p53 transcription and mRNA levels and increases p53-like immunoreactivity and activity. C1-induced caspase-3 activation remained unaffected by the blockade of endocytosis in HEK 293 cells and was abolished in p53-deficient fibroblasts. Conversely, overexpression of the C2 fragment did not significantly sensitize HEK 293 cells to apoptotic stimuli and did not modify p53 mRNA levels or activity. Therefore, the nature of the proteolytic cleavage taking place on PrPc yielded C-terminal catabolites with distinct function and could be seen as a switch mechanism controlling the function of the PrPc in cell survival.
引用
收藏
页码:1956 / 1963
页数:8
相关论文
共 39 条
[1]   Mammalian prion biology: One century of evolving concepts [J].
Aguzzi, A ;
Polymenidou, M .
CELL, 2004, 116 (02) :313-327
[2]   Mayhem of the multiple mechanisms: modelling neurodegeneration in prion disease [J].
Brown, DR .
JOURNAL OF NEUROCHEMISTRY, 2002, 82 (02) :209-215
[3]   TRUNCATED FORMS OF THE HUMAN PRION PROTEIN IN NORMAL BRAIN AND IN PRION DISEASES [J].
CHEN, SG ;
TEPLOW, DB ;
PARCHI, P ;
TELLER, JK ;
GAMBETTI, P ;
AUTILIOGAMBETTI, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (32) :19173-19180
[4]   The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity [J].
Cissé, MA ;
Sunyach, C ;
Lefranc-Jullien, S ;
Postina, R ;
Vincent, B ;
Checler, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (49) :40624-40631
[5]   Wild-type but not Parkinson's disease-related Ala-53 → Thr mutant α-synuclein protects neuronal cells from apoptotic stimuli [J].
da Costa, CA ;
Ancolio, K ;
Checler, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (31) :24065-24069
[6]   Wild-type and mutated presenilins 2 trigger p53-dependent apoptosis and down-regulate presenilin 1 expression in HEK293 human cells and in murine neurons [J].
da Costa, CA ;
Paitel, E ;
Mattson, MP ;
Amson, R ;
Telerman, A ;
Ancolio, K ;
Checler, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (06) :4043-4048
[7]   New insight into abnormal prion protein using monoclonal antibodies [J].
Demart, S ;
Fournier, JG ;
Creminon, C ;
Frobert, Y ;
Lamoury, F ;
Marce, D ;
Lasmézas, C ;
Dormont, D ;
Grassi, J ;
Deslys, JP .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 265 (03) :652-657
[8]   Prion protein prevents human breast carcinoma cell line from tumor necrosis factor α-induced cell death [J].
Diarra-Mehrpour, M ;
Arrabal, S ;
Jalil, A ;
Pinson, X ;
Gaudin, C ;
Piétu, G ;
Pitaval, A ;
Ripoche, H ;
Eloit, M ;
Dormont, D ;
Chouaib, S .
CANCER RESEARCH, 2004, 64 (02) :719-727
[9]   Overexpression and significance of prion protein in gastric cancer and multidrug-resistant gastric carcinoma cell line SGC7901/ADR [J].
Du, JP ;
Pan, YL ;
Shi, YQ ;
Guo, CC ;
Jin, XH ;
Sun, L ;
Liu, N ;
Qiao, T ;
Fan, DM .
INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (02) :213-220
[10]   DEFINITION OF A CONSENSUS BINDING-SITE FOR P53 [J].
ELDEIRY, WS ;
KERN, SE ;
PIETENPOL, JA ;
KINZLER, KW ;
VOGELSTEIN, B .
NATURE GENETICS, 1992, 1 (01) :45-49